CNX-2006 |
| Katalog-Nr.GC11264 |
CNX-2006 ist ein mutantenselektiver und irreversibler EGFR-Inhibitor mit einem IC50-Wert unter 20 nM fÜr EGFRT790M.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1375465-09-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CNX-2006, a structural analog of CO-1686, is a selective and irreversible inhibitor of mutant-EGFR with IC50 value of < 20 nM.
The epidermal growth factor receptor (EGFR) is the cell-surface receptor for epidermal growth factor and plays an important role in tumor invasion and cancer cell proliferation.
CNX-2006 is a novel and irreversible mutant-selective EGFR inhibitor with very weak inhibition of wild-type EGFR. In non-small cell lung cancer (NSCLC) models expressing mutant EGFR-T790M, CNX-2006 inhibited EGFR signaling. CNX-2006 acquired resistance which was drove by NF-κB. So NF-κB activation might replace the EGFR signaling. These results suggested that inhibition of NF-κB pathway was a promising therapy method for patients who progressed after treatment with mutant-selective EGFR inhibitors [1].
Reference:
[1].Galvani E, Sun J, Leon LG, et al. NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor. Oncotarget, 2015.
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *